RAPT Therapeutics — Investor Presentation (January 2020)
37 slides from RAPT Therapeutics's investor presentation, Jan 9, 2020
Slide 1: Transforming the Treatment of Cancer and Inflammation
Transforming the Treatment of Cancer and Inflammation Corporate Presentation January 2020 Exhibit 99.1
Slide 2: Legal Disclaimers
Legal Disclaimers Statements in this presentation (the “Presentation”) for RAPT Therapeutics, Inc. (the “Company,” “we,” or “our”) that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research
Slide 3: Focused on Oral Drugs Targeting Critical Immune Drivers of Disease
DISCOVERY Focused on Oral Drugs Targeting Critical Immune Drivers of Disease FLX475 (Oncology): Selectively targets immunosuppressive tumor Treg Encouraging clinical activity in Phase 1 study Phase 2 PoC readout Q2 2020 RPT193 (Allergic Disease): Oral agent targets inflammatory Th2 cells Robust PK/P
Slide 4: Diversified Pipeline with Significant Inflection Points in 2020
Diversified Pipeline with Significant Inflection Points in 2020 PROGRAM DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Anticipated Program Milestone CCR4 FLX475 Oncology PoC: Q2 2020 RPT193 Inflammation PoC: Q3 2020 GCN2 Oncology Select Candidate: 2020 HPK1 Oncology Asthma and Other Allergic Diseases
Slide 5: Proprietary Drug Discovery and Development Engine
Proprietary Drug Discovery and Development Engine R Drug discovery Clinical development to POC Rapid Interrogating clinically-relevant big datasets to identify targets and biomarkers Driven by data to improve chances of clinical success Critical immune drivers of cancer and inflammation A Analytics
Slide 6: Experienced Leadership Team and Scientific Advisory Board
Experienced Leadership Team and Scientific Advisory Board Leadership Board of Directors Scientific and Clinical Advisors Investors Brian Wong, MD, PhD Chief Executive Officer Dirk Brockstedt, PhD Chief Scientific Officer William Ho, MD, PhD Chief Medical Officer Paul Kassner, PhD Vice President, Qua
Slide 7: Our CCR4 Program
a Our CCR4 Program
Slide 8: CCR4 Drives Tumor Progression and Allergic Inflammation
CCR4 Drives Tumor Progression and Allergic Inflammation Regulatory T cells (Treg) are recruited into the tumor via CCR4 and block antitumor immunity Th2 cells are recruited via CCR4 into tissues and drive allergic inflammation CCR4 Treg CCR4 Th2 Eosinophilia Skin and airway thickening High IgE IL-4
Slide 9: FLX475: CCR4 Antagonist for Oncology
FLX475: CCR4 Antagonist for Oncology
Slide 10: FLX475: Oral CCR4 Antagonist with Phase 2 PoC Anticipated in Q2 2020
FLX475: Oral CCR4 Antagonist with Phase 2 PoC Anticipated in Q2 2020 Designed to selectively block tumor Treg while sparing normal tissues and beneficial immune cells Phase 1/2 study ongoing with PoC readout anticipated in Q2 2020 Demonstrated preliminary evidence of clinical activity Collaborations
Slide 11: Treg Allows Tumors to Evade the Immune System
Treg Allows Tumors to Evade the Immune System Treg are a major barrier to effective antitumor immunity Treg numbers correlate with poor clinical outcome across most tumor types Act as powerful suppressors of the immune response Patients with genetic defects in Treg exhibit severe autoimmunity The CC
Slide 12: Identification and Characterization of "Charged" Tumors
Identification and Characterization of “Charged” Tumors “Charged” tumors: Tumors expressing high levels of CCR4 ligands and Treg Non-Small Cell Lung Cancer Triple Negative Breast Cancer Head and Neck Cancer Virally-Associated Cancers “Charged” tumors tend to be “hot” with high levels of Treg likely
Slide 13: A Large Proportion of Multiple Tumor Types are "Charged"
A Large Proportion of Multiple Tumor Types are “Charged” Tumor Type Prevalence* (U.S.) Virally Associated Percent Viral Estimated Percent “Charged”** Non-Small Cell Lung Cancer 268,600 N/A N/A 60-80% Triple Negative Breast Cancer 145,500 N/A N/A Head and Neck Squamous Cell Carcinoma 143,000 ✓ 25%-60
Slide 14: CCR4 Antagonist: Single Agent Activity in a Mouse Model of a "Charged" Tumor
CCR4 Antagonist: Single Agent Activity in a Mouse Model of a “Charged” Tumor CD8 : Treg Ratio Single Agent Efficacy Tumor Volume (mm3) Days post-inoculation CD8 : Treg ratio Vehicle CCR4 Antagonist Checkpoint Inhibitor Combination *** ** **** * ** P<0.01 *** P<0.001 * P<0.05 **** P<0.0001 ** 400 600
Slide 15: Accumulation of Treg in the TME is a General Adaptive Immune Resistance Mechanism
Accumulation of Treg in the TME is a General Adaptive Immune Resistance Mechanism to Treatment Pre CAR-T Post CAR-T CD8 FoxP3 O’Rourke et al. Science Trans. Med. (2017) Sharma et al. Clinical Cancer Research (2019) Accumulation of Treg has also been observed in both post anti-PD-1 and after conventi
Slide 16: CCR4 Antagonist Synergizes with Checkpoint Inhibitors
CCR4 Antagonist Synergizes with Checkpoint Inhibitors Vehicle CPI 1/10 Tumor-Free CPI + CCR4 Antagonist 5/10 Tumor-Free Treatment initiation Median tumor volume (mm3) Days post-inoculation ** p<0.01 Combination Efficacy 500 1000 0 1500 0 10 20 30 Vehicle Checkpoint Inhibitor CCR4 antagonist + CPI **
Slide 17: FLX475 Clinical Development Status
FLX475 Clinical Development Status Monotherapy 25 mg - 100 mg QD (Mixed tumors including "Charged") Combination w/ Keytruda® 50 mg - 100 mg QD (Mixed tumors including “Charged") 3+3 design Recommended Phase 2 Dose current stage Endpoints: Safety, PK, Biomarkers, Objective Response Rate Phase 1 Healt
Slide 18: Phase 1 Summary
Phase 1 Summary Healthy Volunteer Study 104 healthy human volunteers Target engagement achieved in majority of subjects at 75 mg Excellent safety and tolerability at targeted exposures Oncology Dose Escalation Recommended Phase 2 Dose (Monotherapy): 100 mg Dose escalation for combination cohorts ong
Slide 19: Confirmed Partial Response in a Checkpoint Inhibitor-Refractory NSCLC Patient
Confirmed Partial Response in a Checkpoint Inhibitor-Refractory NSCLC Patient Treated with 50 mg FLX475+Keytruda* 4L NSCLC patient that progressed on prior atezolizumab therapy Confirmed partial response (PR) by RECIST 1.1 criteria. Patient remains on study. Week 14 Screening Week 8 -37.5% (PR) -47%
Slide 20: FLX475 Phase 2 Trial: PoC Expected in Q2 2020
FLX475 Phase 2 Trial: PoC Expected in Q2 2020 FLX475 Monotherapy N=10 FLX475 w/ Keytruda® N=10 N=10 N=10 N=10 N=10 N=10 N=10 Nasopharyngeal (EBV+) Non-Small Cell Lung (CPI Experienced) Hodgkin/Non-Hodgkin (EBV+) Head & Neck (CPI Naïve) Cervical (HPV+) (CPI Naïve) TN Breast (CPI Naïve) Head & Neck (C
Slide 21: RPT193: CCR4 Antagonist for Allergic Diseases
RPT193: CCR4 Antagonist for Allergic Diseases
Slide 22: RPT193: Oral CCR4 Antagonist for Allergic Diseases with PoC Anticipated in Q3 2020
RPT193: Oral CCR4 Antagonist for Allergic Diseases with PoC Anticipated in Q3 2020 Targeting atopic dermatitis, asthma, others Oral convenience could provide substantial competitive advantage to injectables and topical agents Completed IND-enabling studies and healthy volunteer data suggest a favora
Slide 23: RPT193 Acts on a Well Validated Pathway in Asthma and Atopic Dermatitis
RPT193 Acts on a Well Validated Pathway in Asthma and Atopic Dermatitis (AD) RPT193 Inhibits Th2 migration into inflamed tissues anti-IL5/R Ab (Benralizumab, AZ) (Mepolizumab, GSK) anti-IL13 Ab (Lebrikizumab, Dermira) Airway/Skin Allergen IL-5 anti-IL4Rα Ab (Dupilumab, Regeneron/Sanofi) CCR4 Th2 CCL
Slide 24: RPT193 Potential Advantages vs Dupilumab and JAK Inhibitors
RPT193 Dupilumab* JAK inhibitors Safety Preclinical and healthy volunteer data suggest a favorable safety profile Generally safe and well tolerated Conjunctivitis Immunosuppressive Potential black box warning for infections, malignancies and thromboembolic events Route of Administration Oral, daily
Slide 25: Potency of CCR4 Inhibitors in an In Vitro Th2 Chemotaxis Assay
Potency of CCR4 Inhibitors in an In Vitro Th2 Chemotaxis Assay RPT193 AZD2098 GSK2239633 CCL22-Induced Th2 Chemotaxis IC50 ~370nM IC50 ~3µM IC50 ~3µM
Slide 26: RPT193 Demonstrates Similar Efficacy to Biologics in Atopic Dermatitis Model
RPT193 Demonstrates Similar Efficacy to Biologics in Atopic Dermatitis Model Skin Analysis Sensitization Allergen Challenge Treatment: Vehicle, RPT193, Anti-IL-4R, or Anti-IL-13 Days 0 1 7 8 9 10 11 12 Delta Skin Thickness (mm) Days
Slide 27: RPT193 Demonstrates Broader Activity than Anti-IL-13 in an Allergic Asthma Model
RPT193 Demonstrates Broader Activity than Anti-IL-13 in an Allergic Asthma Model p<0.05 Eosinophils Eosinophils in BALF (x106) Neutrophils Neutrophils in BALF (x106) OVA RPT193 Anti-IL-13 Vehicle Vehicle OVA RPT193 Anti-IL-13 IL-5 IL-5 (pg/ml) Vehicle OVA RPT193 Anti-IL-13 24 hrs after day 23 challe
Slide 28: RPT193 Phase 1a/1b Healthy Volunteer/Atopic Dermatitis Trial
RPT193 Phase 1a/1b Healthy Volunteer/ Atopic Dermatitis Trial Mod-Severe AD Readout 4 weeks Placebo-controlled 2:1 ~30 AD Patients ~40-50 Healthy Volunteers Escalating Dose RPT193: Seamless Clinical Trial Design to PoC and Beyond Phase 1a SAD RPT193 Phase 2 Trials Escalating Dose Phase 1a MAD Phase
Slide 29: Phase 1a HV Data Supports Once-Daily Dose
Phase 1a HV Data Supports Once-Daily Dose 100 mg once-daily dose exceeds target exposures and receptor occupancy Favorable safety profile to date (n=56) Target Receptor Occupancy Exceeded at 100 mg Dose-Proportional Oral PK with ~24 Hr. Half-Life
Slide 30: Proposed Phase 2b Double Blind, Placebo-Controlled Trial
RPT193 – dose level 1 ~40 - 60 AD Patients per cohort Proposed Phase 2b Double Blind, Placebo-Controlled Trial Placebo control RPT193 – dose level 2 RPT193 – dose level 3 1:1:1:1 Screening Treatment Period (12-16 wks) Key inclusion criteria: Age ≥ 18 years Mod-Severe AD EASI of ≥ 16 BSA of ≥ 8 IGA ≥
Slide 31: Atopic Dermatitis U.S. Prevalence
Atopic Dermatitis U.S. Prevalence** **2018 Data, Decision Resources, nationaleczema.org, Shaw et al., 2011 Initial RPT193 Target Population Adult Total (~19 M) Adult Diagnosed (~9 M) RPT193: Potentially Disruptive Convenience and Safety Profile Mild ~3.6M Moderate – Severe ~5.4M Moderate – Severe ~2
Slide 32: GCN2 and HPK1: Key Drivers of Tumor Immunosuppression
GCN2 and HPK1: Key Drivers of Tumor Immunosuppression
Slide 33: GCN2 Program: Reversing Tumor Progression Caused by Metabolic Stress
GCN2 Program: Reversing Tumor Progression Caused by Metabolic Stress TME harbors significant metabolic stress GCN2 inhibitors have potential to: Reactivate the immune response Increase tumor cell death Act specifically in the TME resulting in better therapeutic index RAPT GCN2 inhibitor demonstrated
Slide 34: HPK1 Program: Unlocking Antitumor T Cells
HPK1 Program: Unlocking Antitumor T Cells HPK1 is a negative regulator of T cell receptor activation Identified from a RAPT computational screen along with PD-1 and CCR4 High resolution crystal structures and docking models have enabled the discovery of potent and selective HPK1 inhibitors with good
Slide 35: Significant Inflection Points in 2020
Significant Inflection Points in 2020 Timing Milestones FLX475 RPT193 GCN2 Program 2020 1H Phase 2 clinical PoC Phase 1b enrollment completed 2H Expansion cohorts and potential registrational studies Phase 1b clinical PoC Select Candidate
Slide 36: Focused on Oral Drugs Targeting Critical Immune Drivers of Disease
DISCOVERY Focused on Oral Drugs Targeting Critical Immune Drivers of Disease FLX475 (Oncology): Selectively targets immunosuppressive tumor Treg Encouraging clinical activity in Phase 1 study Phase 2 PoC readout Q2 2020 RPT193 (Allergic Disease): Oral agent targets inflammatory Th2 cells Robust PK/P
Slide 37: Thank You
Thank You
RAPT Therapeutics — Investor Presentation (January 2020) on 6ix